Paper · 33879635
SPRY4 suppresses proliferation and induces apoptosis of colorectal cancer cells by repressing oncogene EZH2.
Guo J and 5 others. Aging (Albany NY), 2021. Cited by 13 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. SPRY4 suppresses proliferation and induces apoptosis of colorectal cancer cells by repressing oncogene EZH2. Papers, record 33879635. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33879635
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- SPRY4 suppresses proliferation and induces apoptosis of colorectal cancer cells by repressing oncogene EZH2.
- PubMed
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Colorectal Neoplasms | Major topic |
| Enhancer of Zeste Homolog 2 Protein | Major topic |
| Gene Expression Regulation, Neoplastic | Major topic |
| Intracellular Signaling Peptides and Proteins | Major topic |
| Nerve Tissue Proteins | Major topic |
| Animals | |
| Apoptosis | |
| Cell Line, Tumor | |
| Cell Movement | |
| Cell Proliferation | |
| Gene Knockdown Techniques | |
| Humans | |
| Indoles | |
| Male | |
| Mice | |
| Neoplasm Invasiveness | |
| Pyridones | |
| Xenograft Model Antitumor Assays |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References34
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 16,729,025 | Proapoptotic multidomain Bcl-2/Bax-family proteins: mechanisms, physiological roles, and therapeutic opportunities. | Cell Death Differ | 2006 | https://conductscience.org/library/papers/16729025 | PubMed |
| 2 | 30,387,828 | UBA2 promotes proliferation of colorectal cancer. | Mol Med Rep | 2018 | https://conductscience.org/library/papers/30387828 | PubMed |
| 3 | 25,220,842 | Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. | Int J Cancer | 2015 | https://conductscience.org/library/papers/25220842 | PubMed |
| 4 | 16,337,795 | Sprouty proteins: multifaceted negative-feedback regulators of receptor tyrosine kinase signaling. | Trends Cell Biol | 2006 | https://conductscience.org/library/papers/16337795 | PubMed |
| 5 | 29,540,569 | An EZH2-mediated epigenetic mechanism behind p53-dependent tissue sensitivity to DNA damage. | Proc Natl Acad Sci U S A | 2018 | https://conductscience.org/library/papers/29540569 | PubMed |
| 6 | 26,973,433 | Suppression of Spry4 enhances cancer stem cell properties of human MDA-MB-231 breast carcinoma cells. | Cancer Cell Int | 2016 | https://conductscience.org/library/papers/26973433 | PubMed |
| 7 | 27,899,259 | Overexpression of the long non-coding RNA SPRY4-IT1 promotes tumor cell proliferation and invasion by activating EZH2 in hepatocellular carcinoma. | Biomed Pharmacother | 2017 | https://conductscience.org/library/papers/27899259 | PubMed |
| 8 | 16,388,505 | Sprouty4, a suppressor of tumor cell motility, is down regulated by DNA methylation in human prostate cancer. | Prostate | 2006 | https://conductscience.org/library/papers/16388505 | PubMed |
| 9 | 26,768,617 | Sprouty4 mediates amphiregulin-induced down-regulation of E-cadherin and cell invasion in human ovarian cancer cells. | Tumour Biol | 2016 | https://conductscience.org/library/papers/26768617 | PubMed |
| 10 | 9,458,049 | sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways. | Cell | 1998 | https://conductscience.org/library/papers/9458049 | PubMed |
1 to 10 of 34
See all 34 referencesCited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 13 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40,835,851 | Expression profiles of miR-411 and SPRY4 as indicators of disease progression and treatment in chronic myelogenous leukemia. | Sci Rep | 2025 | https://conductscience.org/library/papers/40835851 | PubMed |
| 40,806,483 | The Lysine at Position 177 Is Essential to Limit the Inhibitory Capacities of Sprouty4 Protein in Normal and Cancer-Derived Cells. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40806483 | PubMed |
| 39,164,253 | Mdm2 requires Sprouty4 to regulate focal adhesion formation and metastasis independent of p53. | Nat Commun | 2024 | https://conductscience.org/library/papers/39164253 | PubMed |
| 38,686,189 | Role of SPRY4 in health and disease. | Front Oncol | 2024 | https://conductscience.org/library/papers/38686189 | PubMed |
| 37,889,057 | SUV39H1 Expression as a Guideline for Omitting Radiotherapy in Lymph Node-positive Triple-negative Breast Cancer Patients. | Cancer Genomics Proteomics | 2023 | https://conductscience.org/library/papers/37889057 | PubMed |
| 36,915,750 | Long noncoding RNA SPRY4-IT1 acts as a miR-101-5p sponge to promote gastrointestinal stromal tumor progression by inhibiting ZEB1. | Am J Transl Res | 2023 | https://conductscience.org/library/papers/36915750 | PubMed |
| 36,384,366 | Sprouty4 is epigenetically upregulated in human colorectal cancer. | Epigenetics | 2023 | https://conductscience.org/library/papers/36384366 | PubMed |
Genes12
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BAX | 581 | PubTator's text mining | https://conductscience.org/library/genes/581 | NCBI Gene |
| BCL2 | 596 | PubTator's text mining | https://conductscience.org/library/genes/596 | NCBI Gene |
| CASP3 | 836 | PubTator's text mining | https://conductscience.org/library/genes/836 | NCBI Gene |
| CYCS | 54,205 | PubTator's text mining | https://conductscience.org/library/genes/54205 | NCBI Gene |
| EZH2 | 2,146 | PubTator's text mining | https://conductscience.org/library/genes/2146 | NCBI Gene |
| MDM2 | 4,193 | PubTator's text mining | https://conductscience.org/library/genes/4193 | NCBI Gene |
| MMP2 | 4,313 | PubTator's text mining | https://conductscience.org/library/genes/4313 | NCBI Gene |
| MMP9 | 4,318 | PubTator's text mining | https://conductscience.org/library/genes/4318 | NCBI Gene |
| POTEF | 728,378 | PubTator's text mining | https://conductscience.org/library/genes/728378 | NCBI Gene |
| SPRY4 | 81,848 | PubTator's text mining | https://conductscience.org/library/genes/81848 | NCBI Gene |
1 to 10 of 12
See all 12 genesDrugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33879635
GET https://conductscience.org/api/papers/v1/33879635/references?page=2